


AstraZeneca Open Innovation: Concept proposal instructions for authors

Preclinical Research Proposals

Concept proposals should be brief (2-3 pages) and focus on novel translational research that advances the understanding of the target mechanism(s) in disease in areas of unmet medical need. The output of the research should provide further insight to disease pathophysiology and be able to support the development of potential new therapies.




Note:

- **Out of scope:** Standalone experiments that only look at pharmacokinetic or safety parameters, screening assays using multiple compounds and clinical studies should not be included in these preclinical research proposals.
- **Confidential information:** Please include only **non-confidential** in the concept proposal. If confidential data exists that would strengthen the proposal, the author may indicate that confidential information is available to share under a Confidential Disclosure Agreement (CDA). If AstraZeneca finds the non-confidential Concept Proposal sufficiently interesting, we will discuss about executing a CDA.
- **Technology Transfer Office contact:** We request that you include in your application the name and contact details for your Technology Transfer Office. Preferably this should be an individual with whom you have already discussed your submission. Upon acceptance of your proposal, the contract can then be sent directly to this individual as well as to the submitter.
- **Additional details:** During the submission process, additional details regarding the use of human tissue and/or animals may be requested.

Clinical or Translational Research Proposals

Concept proposals should be brief (maximum 5 pages) and include:



Note:

Only **non-confidential** information should be included in a *Concept Proposal*. If confidential data exists that would strengthen the proposal, the author may indicate that confidential information is available to share under a Confidential Disclosure Agreement (CDA). If AstraZeneca finds the non-confidential Concept Proposal sufficiently interesting, execution of a CDA will be discussed.